JP2016512323A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016512323A5 JP2016512323A5 JP2015560717A JP2015560717A JP2016512323A5 JP 2016512323 A5 JP2016512323 A5 JP 2016512323A5 JP 2015560717 A JP2015560717 A JP 2015560717A JP 2015560717 A JP2015560717 A JP 2015560717A JP 2016512323 A5 JP2016512323 A5 JP 2016512323A5
- Authority
- JP
- Japan
- Prior art keywords
- pth
- human pth
- peptide
- antibody
- oxidized
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000445 Parathyroid hormone Proteins 0.000 claims description 37
- 101001135770 Homo sapiens Parathyroid hormone Proteins 0.000 claims description 35
- 101001135995 Homo sapiens Probable peptidyl-tRNA hydrolase Proteins 0.000 claims description 35
- 102000058004 human PTH Human genes 0.000 claims description 27
- 102100036893 Parathyroid hormone Human genes 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 19
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 15
- 150000001413 amino acids Chemical class 0.000 claims description 14
- 239000000199 parathyroid hormone Substances 0.000 claims description 12
- 102000003982 Parathyroid hormone Human genes 0.000 claims description 8
- 210000003734 kidney Anatomy 0.000 claims description 8
- 230000036542 oxidative stress Effects 0.000 claims description 8
- 239000012634 fragment Substances 0.000 claims description 7
- 229960001319 parathyroid hormone Drugs 0.000 claims description 7
- 238000005259 measurement Methods 0.000 claims description 6
- 210000002966 serum Anatomy 0.000 claims description 6
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 5
- 208000020832 chronic kidney disease Diseases 0.000 claims description 5
- 238000001631 haemodialysis Methods 0.000 claims description 5
- 230000000322 hemodialysis Effects 0.000 claims description 5
- 229930182817 methionine Natural products 0.000 claims description 5
- 102000005962 receptors Human genes 0.000 claims description 5
- 108020003175 receptors Proteins 0.000 claims description 5
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 4
- 230000000890 antigenic effect Effects 0.000 claims description 4
- 230000017531 blood circulation Effects 0.000 claims description 4
- 238000003018 immunoassay Methods 0.000 claims description 4
- 230000004913 activation Effects 0.000 claims description 3
- 230000000849 parathyroid Effects 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 2
- 208000037157 Azotemia Diseases 0.000 claims description 2
- 201000002980 Hyperparathyroidism Diseases 0.000 claims description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 238000002651 drug therapy Methods 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 238000012544 monitoring process Methods 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 208000009852 uremia Diseases 0.000 claims description 2
- 239000004474 valine Substances 0.000 claims description 2
- 239000007790 solid phase Substances 0.000 claims 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims 1
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 4
- 235000006109 methionine Nutrition 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 3
- 238000001050 pharmacotherapy Methods 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 150000002742 methionines Chemical group 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13158401.3A EP2775306B1 (en) | 2013-03-08 | 2013-03-08 | Non-oxidized, biological active parathyroid hormone determines mortality in hemodialysis patients |
| EP13158401.3 | 2013-03-08 | ||
| PCT/EP2014/054508 WO2014135701A1 (en) | 2013-03-08 | 2014-03-07 | Non-oxidized, biological active parathyroid hormone determines mortality in hemodialysis patients |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016512323A JP2016512323A (ja) | 2016-04-25 |
| JP2016512323A5 true JP2016512323A5 (cg-RX-API-DMAC7.html) | 2017-04-06 |
| JP6526577B2 JP6526577B2 (ja) | 2019-06-05 |
Family
ID=47827083
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015560717A Active JP6526577B2 (ja) | 2013-03-08 | 2014-03-07 | 非酸化の生物学的に活性な副甲状腺ホルモンは血液透析患者における死亡率を決定する |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10613101B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2775306B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6526577B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2904433A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2689193T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014135701A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2714565T3 (es) | 2014-02-20 | 2019-05-29 | Immundiagnostik Ag | Diagnóstico in vitro y pronóstico de nefropatía inducida por contraste (nic) en pacientes sometidos a angiografía coronaria |
| EP3499235A1 (en) | 2017-12-13 | 2019-06-19 | Immundiagnostik AG | Method of measuring auto-antibodies in bodily fluids |
| WO2019141791A1 (en) * | 2018-01-17 | 2019-07-25 | Immundiagnostik Ag | Biomarker predicting coronary artery disease |
| ES2984718T3 (es) | 2018-08-20 | 2024-10-30 | Immundiagnostik Ag | Composición de sorbente para el tratamiento preanalítico de muestras |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1988006596A1 (en) | 1987-03-02 | 1988-09-07 | Bissendorf Peptide Gmbh | New cardiodilatin fragment, process for preparing same and use thereof |
| CA2040264A1 (en) | 1990-04-12 | 1991-10-13 | Tatsuhiko Kanmera | Parathyroid hormone antagonists |
| DE4434551A1 (de) | 1994-09-28 | 1996-04-04 | Forssmann Wolf Georg Prof Dr D | Peptide aus der Sequenz des hPTH (1-37) |
| US6689566B1 (en) | 1999-01-14 | 2004-02-10 | Scantibodies Laboratory, Inc. | Methods, kits, and antibodies for detecting parathyroid hormone |
| DE19961350A1 (de) | 1999-12-17 | 2001-06-21 | Immundiagnostik Ag | Verfahren zur Bestimmung der Parathormon-Aktivität in einer menschlichen Probe |
| DE10116552A1 (de) * | 2001-04-03 | 2002-10-10 | Abc Armbruster Biochemicals | Verfahren zur Bestimmung der wirksamen Parathormon-Aktivität in einer Probe |
| US20030082179A1 (en) | 2001-07-03 | 2003-05-01 | Hutchison James Scott | Parathyroid hormone antibodies and related methods |
| EP2631247A1 (en) * | 2012-02-22 | 2013-08-28 | Immundiagnostik AG | Means and methods of measuring parathyroid hormone in patients suffering from oxidative stress |
-
2013
- 2013-03-08 ES ES13158401.3T patent/ES2689193T3/es active Active
- 2013-03-08 EP EP13158401.3A patent/EP2775306B1/en active Active
-
2014
- 2014-03-07 JP JP2015560717A patent/JP6526577B2/ja active Active
- 2014-03-07 US US14/773,619 patent/US10613101B2/en active Active
- 2014-03-07 CA CA2904433A patent/CA2904433A1/en not_active Abandoned
- 2014-03-07 WO PCT/EP2014/054508 patent/WO2014135701A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5419968B2 (ja) | 心臓治療を必要とする個体におけるｌ−ｆａｂｐ、ナトリウム利尿ペプチド及び心筋トロポニン | |
| Mogues et al. | IgG antibodies against bovine serum albumin in humans—their prevalence and response to exposure to bovine serum albumin | |
| JP2016512323A5 (cg-RX-API-DMAC7.html) | ||
| KR20190006614A (ko) | 급성 신장 손상의 발견 또는 감시 방법, 장치 및 키트 | |
| Szabo et al. | Measurement of anti-beta amyloid antibodies in human blood | |
| JP6526577B2 (ja) | 非酸化の生物学的に活性な副甲状腺ホルモンは血液透析患者における死亡率を決定する | |
| RU2013158334A (ru) | Средства и способы диагностики и лечения рассеянного склероза | |
| JP6515923B2 (ja) | クレアチンキナーゼｍｂアイソザイムの測定方法及びそれに用いられるキット | |
| NZ591918A (en) | Antibodies to modified human igf-1/e peptides | |
| Spagnoli et al. | Evaluation of the components of insulin‐like growth factor (IGF)‐IGF binding protein (IGFBP) system in adolescents with type 1 diabetes and persistent microalbuminuria: relationship with increased urinary excretion of IGFBP‐3 18 kD N‐terminal fragment | |
| WO2024061128A1 (zh) | 盘状结构域受体2在诊断神经退行性疾病中的应用及相关的计算机可读介质 | |
| US20120183527A1 (en) | Measurement of anti-amyloid antibodies in human blood | |
| Alouffi et al. | Depression and smoking augment the production of circulating autoantibodies against glycated HSA in rheumatoid arthritis patients | |
| JP6873995B2 (ja) | ヘプシジンの検出用キット | |
| JP2011202964A (ja) | バイオマーカーとしてのプロパノイルリジン、プロパノイルリジンの使用、及び検査用試薬キット | |
| JP2010513917A (ja) | ロングペントラキシンｐｔｘ３の血漿レベルを測定するための方法 | |
| US20230417761A1 (en) | Detection and quantification of natalizumab | |
| Borromeo et al. | Monoclonal antibodies as a probe for the unfolding of porcine growth hormone | |
| JP2016535266A5 (cg-RX-API-DMAC7.html) | ||
| Bentli et al. | Serum asymmetric-dimethylarginine, apelin and NT-pro BNP levels in dialysis patients | |
| Lee et al. | Association between the ratio of insulin-like growth factor-I to insulin-like growth factor binding protein-3 and inflammation in incident automated peritoneal dialysis patients | |
| JP2015503106A5 (cg-RX-API-DMAC7.html) | ||
| CN110467665A (zh) | 闭锁蛋白31kDa降解片段的特异性抗原表位肽及其应用 | |
| JPWO2009069528A1 (ja) | 疲労度の評価方法及び疲労度を評価するためのキット | |
| Ishii et al. | Development of an Enzyme-Linked Immunosorbent Assay for Protein 1¹ |